PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Unit of Adverse Drug Reactions Monitoring, Pisa, Italy.\', \'Department of Clinical and Experimental Medicine, Unit of Pharmacology and Pharmacovigilance, University of Pisa, Pisa, Italy.\', \'North Western Tuscany Blood Bank, University Hospital of Pisa, Pisa, Italy.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/17460441.2021.1960819
?:doi
?:hasPublicationType
?:journal
  • Expert opinion on drug discovery
is ?:pmid of
?:pmid
?:pmid
  • 34304682
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.309
?:rankingScore_hIndex
  • 46
?:title
  • An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34304682>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34304682>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all